undamentalytics Newsletter
Sign in

Editas Medicine, Inc. cash flow statement

In fiscal 2025, Editas Medicine, Inc.'s operations generated −$165m of cash; it spent $607,000 on capital projects, leaving free cash flow of −$166m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−50−9−46−41−180−164−177−132−210−165−120
Depreciation and amortisation13334566652
Stock-based pay172327272343292021109
Capital spending32567845911
Free cash flow−54−11−50−47−187−172−181−137−219−166−121
Free cash flow after stock pay−71−35−77−74−210−215−211−157−241−176−129
Shares issued97154771162042490117043152

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EDIT vs SPROEDIT vs STROEDIT vs OCUL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Editas Medicine, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Editas Medicine, Inc.